CLAIMS

1. Use of an effective amount of a nanoparticle composition comprising paclitaxel coated with an albumin in the manufacture of a first medicament for treating cancer in an individual, and use of an effective amount of a PD-1 pathway antagonist in the manufacture of a second medicament for treating cancer in the individual, wherein the first medicament and the second medicament are to be administered to the individual.

2. The use according to claim 1, wherein said antagonist is an antagonist of PD-1 or an antagonist of a ligand of PD-1.

3. The use according to claims 1 or 2, wherein said antagonist is an antibody.

4. The use according to any one of claims 1-3, wherein said antibody is a monoclonal antibody.

5. The use according to any one of claims 1-4, wherein said antibody is a humanized antibody or fully human antibody.

6. The use according to any one of claims 3-5, wherein said antibody is an immunoglobulin G (IgG) antibody.

7. The use according to claim 6, wherein said IgG antibody is an IgG4 antibody.

8. The use according to claim 2, wherein said antagonist is selected from the group consisting of AMP-224, BMS-936559, MEDI4736, MSB0010718C, MPDL3280A, nivolumab, AMP-514, pembrolizumab (MK-3475), REGN2810, PDR001, BGB-A317, and pidilizumab (CT-011).

9. The use according to any one of claims 1-8, wherein said antagonist is an antagonist of PD-1.

10. The use according to claim 9, wherein said antagonist of PD-1 is an anti-PD-1 antibody.

11. The use according to claim 10, wherein said anti-PD-1 antibody is nivolumab, AMP 514, pembrolizumab (MK-3475), REGN2810, PDR001, BGB-A317, or pidilizumab (CT-011).

12. The use according to claim 11, wherein said anti-PD-1 antibody is nivolumab, AMP 514, pembrolizumab (MK-3475), or pidilizumab (CT-011).

13. The use of claim 11, wherein the anti-PD-1 antibody is BGB-A317.

14. The use of claim 11, wherein the anti-PD-1 antibody is nivolumab.

15. The use of any one of claims 1-8, wherein said other agent is an antagonist of PD-L1.

16. The use of claim 15, wherein said antagonist of PD-L1 is an anti-PD-L1 antibody.

17. The use of claim 16, wherein said anti-PD-L1 antibody is BMS-936559, MSB0010718C, MPDL3280A, or MEDI4736.

18. The use of claim 17, wherein said anti-PD-L1 antibody is BMS-936559, MPDL3280A, or MEDI4736.

19. The use of claim 17, wherein said anti-PD-L1 antibody is MPDL3280A.

20. The use according to any one of claims 1-19, wherein a chemotherapeutic agent is to be further administered to said individual.

21. The use according to claim 20, wherein said chemotherapeutic agent is a platinum-based agent.

22. The use according to claim 21, wherein said platinum-based agent is carboplatin.

23. The use according to claim 21, wherein said platinum-based agent is cisplatin.

24. The use according to claim 20, wherein said chemotherapeutic agent is a nucleoside analog.

25. The use according to claim 24, wherein said nucleoside analog is gemcitabine.

26. The use according to any one of claims 1-25, wherein said cancer is breast cancer.

27. The use according to claim 26, wherein said individual is negative for ER, PR, or HER2.

28. The use according to claim 26 or 27, wherein said breast cancer is a Her2(-) breast cancer.

29. The use according to any one of claims 26-28, wherein said breast cancer is a metastatic breast cancer.

30. The use according to any one of claims 26-29, wherein said breast cancer is a recurrent breast cancer.

31. The use according to any one of claims 1-25, wherein said cancer is a pancreatic cancer.

32. The use according to any one of claims 1-25, wherein said cancer is a lung cancer.

33. The use according to claim 32, wherein said lung cancer is a non-small cell lung cancer (NSCLC).

34. The use according to claim 33, wherein said NSCLC is a stage III or stage IV NSCLC.

35. The use according to claim 33, wherein said NSCLC is a stage IIIB NSCLC.

36. The use according to any one of claims 1-35, wherein said first medicament and said second medicament are to be administered simultaneously or concurrently.

37. The use according to any one of claims 1-35, wherein said first medicament and said second medicament are to be administered sequentially.

38. The use according to any one of claims 20-35, wherein said first medicament, said second medicament and said chemotherapeutic agent are to be administered simultaneously or concurrently.

39. The use according to any one of claims 20-35, wherein said first medicament, said second medicament, and said chemotherapeutic agent are to be administered sequentially.

40. The use according to any one of claims 1-39, wherein said nanoparticles in said composition have an average diameter of less than or equal to 200 nm.

41. The use according to any one of claims 1-40, wherein said albumin and said paclitaxel in said nanoparticle composition have a weight ratio from 1:1 to 18:1.

42. The use according to any one of claims 1-40, wherein said albumin and said paclitaxel in said nanoparticle composition have a weight ratio from 1:1 to 9:1.

43. The use of any one of claims 1-40, wherein said albumin and said paclitaxel in said nanoparticle composition have a weight ratio of 9:1.

44. The use according to any one of claims 1-43, wherein said individual is a human.

45. The use according to any of claims 1-44, wherein the first medicament and the second medicament are to be administered via intravenous administration.

46. A kit comprising: a) an effective amount of a nanoparticle composition comprising paclitaxel coated with an albumin, and b) an effective amount of a PD-1 pathway antagonist.

47. A pharmaceutical composition comprising: a) an effective amount of a nanoparticle composition comprising paclitaxel coated with an albumin, and b) an effective amount of a PD-1 pathway antagonist.

48. The kit of claim 46 or the pharmaceutical composition of claim 47, wherein said antagonist is an anti-PD-1 antibody.

49. The kit or pharmaceutical composition of claim 48, wherein said anti-PD-1 antibody is nivolumab.

50. The kit or pharmaceutical composition of claim 48, wherein said anti-PD-1 antibody is BGB-A317.

51. The kit of claim 47 or the pharmaceutical composition of claim 48, wherein said antagonist is an anti-PD-L1 antibody.

52. The kit or pharmaceutical composition of claim 51, wherein said anti-PD-L1 antibody is MPDL3280A.

53. Use of an effective amount of a nanoparticle composition comprising paclitaxel coated with an albumin in the manufacture of a first medicament for treating breast cancer in an individual, and use of an effective amount of an anti-PD-L1 antibody in the manufacture

of a second medicament for treating breast cancer in an individual, wherein the first medicament comprising the effective amount of the nanoparticle composition and the second medicament comprising the effective amount of the anti-PD-L1 antibody are to be administered to the individual; wherein the effective amount of the nanoparticle composition is from 60 mg/m^2 to 300 mg/m^2.

54. The use of claim 53, wherein the effective amount of the nanoparticle composition is from 80 mg/m^2 to 200 mg/m^2.

55. The use of claim 53, wherein the effective amount of the nanoparticle composition is 100 mg/m^2.

56. The use of claim any one of claims 53-55, wherein said anti-PD-L1 antibody is BMS-936559, MSB0010718C, MPDL3280A, or MEDI4736.

57. The use of claim 56, wherein said anti-PD-L1 antibody is BMS-936559, MPDL3280A, or MEDI4736.

58. The use of claim 56, wherein said anti-PD-L1 antibody is MPDL3280A.

59. The use of any one of claims 53-58, wherein the effective amount of the anti-PD-L1 antibody is from 0.1 mg/kg to 20 mg/kg or from 0.1 mg/kg to 10 mg/kg.

60. The use of any one of claims 53-58, wherein the effective amount of the anti-PD-L1 antibody is from 500 mg to 1500 mg.

61. The use of any one of claims 53-60, wherein said individual is negative for ER, PR, or HER2.

62. The use of any one of claims 53-61, wherein said breast cancer is a metastatic breast cancer.

63. The use of any one of claims 53-62, wherein said breast cancer is a recurrent breast cancer.

64. The use of any one of claims 53-63, wherein the first medicament is to be administered on days 1, 8, and 15 of a 28-day cycle and wherein the second medicament is to be administered on days 1 and 15 of a 28-day cycle.

65. The use of any one of claims 53-64, wherein the first medicament and the second medicament are to be administered via intravenous administration.

66. Use of an effective amount of a nanoparticle composition comprising paclitaxel coated with an albumin in the manufacture of a first medicament for treating pancreatic cancer in an individual, and use of an effective amount of an effective amount of an anti-PD-1 antibody in the manufacture of a second medicament for treating pancreatic cancer in an individual, wherein the first medicament comprising the effective amount of the nanoparticle composition and the second medicament comprising the effective amount of the anti-PD-1 antibody are to be administered to the individual; and wherein the effective amount of the nanoparticle composition is from 60 mg/m^2 to 300 mg/m^2.

67. The use of claim 66, wherein the effective amount of the nanoparticle composition is from 80 mg/m^2 to 200 mg/m^2.

68. The use of claim 66, wherein the effective amount of the nanoparticle composition is 100 mg/m^2.

69. The use of any one of claims 66-68, wherein the anti-PD-1 antibody is nivolumab, AMP 514, pembrolizumab (MK-3475), REGN2810, PDR001, BGB-A317, or pidilizumab (CT-011).

70. The use of any one of claims 66-69, wherein said anti-PD-1 antibody is nivolumab.

71. The use of any one of claims 66-70, wherein the effective amount of the anti-PD-1 antibody is from 0.1 mg/kg to 10 mg/kg.

72. The use of any one of claims 66-71, wherein the effective amount of the anti-PD-1 antibody is 3 mg/kg.

73. The use of any one of claims 66-72, wherein gemcitabine is to be further administered to the individual.

74. The use of claim 73, wherein the gemcitabine is in an amount from 500 mg to 1500 mg.

75. The use of claim 73 or claim 74, wherein the gemcitabine is in an amount of 600 mg, 800 mg, 1000 mg, or 1500 mg.

76. The use of any one of claims 66-75, wherein the first medicament is to be administered on days 1, 8, and 15 of a 28-day cycle and wherein the second medicament is to be administered on days 1 and 15 of a 28-day cycle.

77. The use of any one of claims 66-76, wherein the first medicament and the second medicament are to be administered via intravenous administration.

78. Use of an effective amount of a nanoparticle composition comprising paclitaxel coated with an albumin in the manufacture of a first medicament for treating lung cancer in an individual, use of an effective amount of carboplatin in the manufacture of a second medicament for treating lung cancer in an individual, and use of an effective amount of an anti-PD-1 antibody in the manufacture of a third medicament for treating lung cancer in an individual, wherein the first medicament comprising the effective amount of the nanoparticle composition, the second medicament comprising the effective amount of the carboplatin, and the third medicament comprising the effective amount of the anti-PD-1 antibody are to be administered to the individual; wherein the wherein the effective amount of the nanoparticle composition is from 60 mg/m^2 to 300 mg/m^2.

79. The use of claim 78, wherein the effective amount of the nanoparticle composition is from 80 mg/m^2 to 200 mg/m^2.

80. The use of claim 78, wherein the effective amount of the nanoparticle composition is 100 mg/m^2.

81. The use of any one of claims 78-80, wherein the anti-PD-1 antibody is nivolumab, AMP 514, pembrolizumab (MK-3475), REGN2810, PDR001, BGB-A317, or pidilizumab (CT-011).

82. The use of any one of claims 78-81, wherein the anti-PD-1 antibody is nivolumab.

83. The use of any one of claims 78-82, wherein the effective amount of the anti-PD-1 antibody is from 0.1 mg/kg to 10 mg/kg.

84. The use of any one of claims 78-83, wherein the effective amount of the anti-PD-1 antibody is 5 mg/kg.

85. The use of any one of claims 78-83, wherein the effective amount of the anti-PD-1 antibody is 3 mg/kg .

86. The use of claim any one of claims 78-85, wherein the first medicament is to be administered on days 1, 8, and/or 15 of a 21-day cycle; and wherein the third medicament is to be administered on day 15 of a 21-day cycle.

87. The use according to any one of claims 78-86, wherein said lung cancer is a non-small cell lung cancer (NSCLC).

88. The use according to claim 87, wherein said NSCLC is a stage III or stage IV NSCLC.

89. The use according to claim 87, wherein said NSCLC is a stage IIIB NSCLC.

90. The use according to any one of claims 78-89, wherein the first medicament, the second medicament and the third medicament are to be administered via intravenous administration.